Sale strategies of pharmaceutical companies in a “pharmerging” country: The problems will not improve if the gaps remain-Reference-Cited by-同舟云学术

Sale strategies of pharmaceutical companies in a “pharmerging” country: The problems will not improve if the gaps remain

Published:2012-08 Issue:3 Volume:106 Page:225-232
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Civaner Murat

Publisher

Elsevier BV

Subject

Health Policy

Reference56 articles.

1. IMS. IMS health lowers 2009 global pharmaceutical market forecast to 2.5–3.5 percent growth, http://getir.net/za42; 2009.

2. Public Citizen. 2002 Drug industry profits: hefty pharmaceutical company margins dwarf other industries. Washington: Public Citizen's Congress Watch, 2003:6.

3. Kaiser Foundation. Trends in promotional spending for prescription drugs, 1996–2007, http://facts.kff.org/chart.aspx?ch=225; 2009.

4. No more free lunches;Abbasi;BMJ,2003

5. Unhealthy spin;Burton;BMJ,2003

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial efficiency of healthcare companies in an emerging market;Managerial and Decision Economics;2024-04-04

2. Raising the bar for disclosure of industry payments to doctors;BMJ;2024-02-29

3. Analysis of the pharmaceutical market for sorption drugs in Russia and the European Union;Legal regulation in veterinary medicine;2024-01-26

4. The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities;Terra Economicus;2023-09-25

5. Is the “social face” of AKP's pharmaceutical price reforms mostly instrumental? A progressivity analysis of household pharmaceutical expenditures in Turkey;Public Health;2022-07